Blockade of BAFF in mice disrupts TLSs and ameliorates nephritis [61], while in humans, BAFF expression correlates with TLS‐like B cell aggregates and disease severity [62, 63], suggesting potential therapeutic benefit from targeting BAFF in lupus nephritis. Here, TNFSF13B is linked to lupus nephritis.